ArticleFrontiers in oncology2021
Trends in Intracranial Glioma Incidence and Mortality in the United States, 1975-2018.
Article in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 74 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
74 citing papers in PubMed, 3 syntheses or guidelines pooled it, 110 citations in OpenAlex.
- Pooled it
- Coffee and tea consumption and glioma risk: a meta-analysis of cohort studies.Frontiers in nutrition · 2024Pooled it
- A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review.International journal of molecular sciences · 2022Pooled it
- Pembrolizumab monotherapy for microsatellite instability-high or mismatch repair deficient recurrent gliomas: results from the multicohort KEYNOTE-158 study.Journal of neuro-oncology · 2026Trial
- Associations between migrasome-related genes and long non-coding rnas in glioma and their prognostic relevance to the tumor microenvironment.IBRO neuroscience reports · 2026Article
- Proton Bragg peak flash stereotactic radiosurgery for recurrent glioblastoma reirradiation.Physics and imaging in radiation oncology · 2026Article
- Tasimelteon inhibits glioma proliferation by inducing ferroptosis via the SP1/ACSL4 pathway.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Evaluation of triphenyl phosphate's pathogenic potential and molecular mechanisms in glioblastoma: an integrated network toxicology investigation employing multiple machine learning approaches.Translational cancer research · 2026Article
- Plant-derived nanocarriers & nanostructures for barrier-defined translation: a comprehensive review of mechanisms, targets, and translation.Journal of nanobiotechnology · 2026Review
- An Updated Narrative Review on the Therapeutic Potential of Resveratrol in the Treatment of Cancer.Health science reports · 2026Article
- The safety and efficacy of bispecific T-cell engagers (TCEs) in patients with glioma.Clinical and experimental medicine · 2026Review
- Mathematical Modeling of the Role of Cytokines in Sindbis Virus Treatment of Glioblastoma.CPT: pharmacometrics & systems pharmacology · 2026Article
- Review
- Lactylation in cancer: molecular mechanisms and advances in clinical study.Molecular cancer · 2026Review
- Designing a web-based platform for dynamic estimation of individualized conditional survival in grade 3 gliomas.Discover oncology · 2025Article
- Targeting autophagy and plasminogen activator inhibitor-1 increases survival and remodels the tumor microenvironment in glioblastoma.Journal of experimental & clinical cancer research : CR · 2025Article
- Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of ovarian cancer.Cancer cell international · 2025Article
- Prevalence and Independent Risk Factors of Anxiety and Depression Symptoms in Glioma Patients: A Cross-Sectional Analysis.Psychiatry and clinical psychopharmacology · 2025Article
- Article
- Metformin and glioma: Targeting metabolic dysregulation for enhanced therapeutic outcomes.Translational oncology · 2025Review
14 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeGlioma incidence in the US seems to have stabilized over the past 20 years. It's also not clear whether changes in glioblastoma incidence are associated with glioma mortality trends. Our study investigated trends in glioma incidence and mortality according to tumor characteristics.
methodsThis study obtained data from the Surveillance, Epidemiology, and End Results-9 (SEER-9) registries to calculate glioma incidence and mortality trends. Annual percent changes (APC) and 95% CIs were calculated using the Joinpoint program.
results62,159 patients (34,996 males and 55,424 whites) were diagnosed with glioma during 1975-2018, and 31,922 deaths occurred from 1995-2018. Glioblastoma (32,893 cases) and non-glioblastoma astrocytoma (17,406 cases) were the most common histologic types. During the study period, the incidence of glioma first experienced a significant increase (APC=1.8%, [95% CI, 1.3% to 2.3%]) from 1975 to 1987, and then experienced a slight decrease (APC=-0.4%, [95% CI, -0.5% to -0.3%]) from 1987 to 2018, while the APC was 0.8% for glioblastoma, -2.0% for non-glioblastoma astrocytoma, 1.1% for oligodendroglial tumors, 0.7% for ependymoma and -0.3% for glioma NOS during the study period. Glioblastoma incidence increased for all tumor size and tumor extension except for distant. From 1995 to 2018, glioma mortality declined 0.4% per year (95% CI: -0.6% to -0.2%) but only increased in patients older than 80 years [APC=1.0%, (95% CI, 0.4% to 1.6%)].
conclusionSignificant decline in glioma incidence (1987-2018) and mortality (1995-2018) were observed. Epidemiological changes in non-glioblastoma astrocytoma contributed the most to overall trends in glioma incidence and mortality. These findings can improve understanding of risk factors and guide the focus of glioma therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.